Claims for Patent: 5,242,901

Summary for Patent: 5,242,901

Title:	Reduction of anthracycline induced cardiotoxicity
Abstract:	Disclosed is a method for preventing cardiotoxicity in a human in need of such preventive treatment, the method including administering an effective amount of a bisdioxopiperazine. Also disclosed is a method for preventing cardiotoxicity induced by the administration of an anthracycline. Further, a tumoricidal, cardioprotective combination of agents is disclosed.
Inventor(s):	Speyer; James L. (New York, NY), Muggia; Franco M. (Los Angeles, CA), Green; Michael D. (North Carlton, AU)
Assignee:	New York University (New York, NY)
Application Number:	07/860,581
Patent Claims:	1. A method of preventing cardiotoxicity in a human caused by the administration of an anthracycline, comprising: administering an effective amount of bisdioxopiperazine to said human. 2. The method of claim 1 wherein said bisdioxopiperazine is (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. 3. The method of claim 1 wherein said cardiotoxicity is caused by administration of a combination of an anthracycline and at least one member selected from the group consisting of fluorouracil, cyclophosphamide, vincristine, bleomycin, prednisone, cisplatin, vinblastine, and dacarbazine. 4. The method of claim 3, wherein said anthracycline is doxorubicin. 5. The method of claim 1 wherein said cardiotoxicity is caused by administration of a combination of doxorubicin, fluorouracil and cyclophosphamide. 6. The method of claim 1 wherein said human suffers from a malignant tumor responsive to said anthracycline. 7. A non-cardiotoxic method of treating cancer in a human in need of such treatment, comprising: administering an effective amount of a bisdioxopiperazine to said human; and administering an effective amount of an anthracycline. 8. The method of claim 7 wherein said bisdioxopiperazine is (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. 9. The method of claim 8, wherein said anthracycline is doxorubicin. 10. The method of claim 8 wherein said anthracycline is administered in combination with at least one other chemotherapeutic agent. 11. The method of claim 10 wherein said chemotherapeutic agent is selected from the group consisting of fluorouracil, cyclophosphamide, vincristine, bleomycin, prednisone, cisplatin, vinblastine, and dacarbazine. 12. The method of claim 10, wherein said anthracycline is doxorubicin. 13. The method of claim 11 wherein said combination is doxorubicin, fluorouracil and cyclophosphamide. 14. The method of claim 7 wherein said cancer is selected from the group consisting of breast adenocarcinoma and lung cancer.